EFFICACY OF CD28 ANTIBODY FOR GVHD PREVENTION

CD28 抗体预防 GVHD 的功效

• 批准号: 8172753
• 负责人: PAUL J MARTIN
• 金额: $ 15.51万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-01 至 2011-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8172753
• 关键词: Antibodies; Binding; Blood; Bone Marrow; CD28 gene; Canis familiaris; Cells; Computer Retrieval of Information on Scientific Projects Database; Disease; Funding; Grant; Human; Immune; Institution; Mus; Pilot Projects; Prevention; Procedures; Reaction; Research; Research Personnel; Resources; Source; Testing; Transplantation; United States National Institutes of Health; nonhuman primate; prevent

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A variety of diseases can be cured by bone marrow or blood transplantation, but this procedure is frequently complicated by a harmful immune reaction of donor cells against the recipient. Previous studies have shown that an agonistic CD28-specific antibody that binds to donor cells can prevent this immune reaction in mice. We have made a similar antibody that binds to human donor cells, but we do not know whether this antibody could prevent the immune reaction after bone marrow or blood transplantation. This antibody also binds to non-human primate donor cells but not against dog or mouse donor cells. The FDA will not allow testing of the antibody in humans, unless prior testing has been done in nonhuman primates to show that the antibody is safe and effective. The pilot study proposed in this application is intended to provide initial information that could be used to assess the merits of further studies with the use of this antibody as a way of preventing immune reactions after bone marrow or blood transplantation. The results of this project showed that the CD28 antibody did not prevent the harmful immune reaction of donor cells against the recipient. The project has been closed.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 许多疾病可以通过骨髓或血液移植治愈，但这一过程经常因供体细胞对受体的有害免疫反应而复杂化。先前的研究表明，与供体细胞结合的激动性CD 28特异性抗体可以阻止小鼠的这种免疫反应。我们已经制造了一种与人类供体细胞结合的类似抗体，但我们不知道这种抗体是否可以阻止骨髓或血液移植后的免疫反应。该抗体也结合非人灵长类动物供体细胞，但不结合狗或小鼠供体细胞。 FDA将不允许在人类中进行抗体测试，除非之前已经在非人灵长类动物中进行了测试，以证明抗体是安全有效的。本申请中提出的试点研究旨在提供初步信息，可用于评估使用该抗体作为预防骨髓或血液移植后免疫反应的方法的进一步研究的优点。 该项目的结果表明，CD 28抗体不能阻止供体细胞对受体的有害免疫反应。该项目已关闭。